The effect of azithromycin on ivermectin pharmacokinetics - A population pharmacokinetic model analysis

PLoS Neglected Tropical Diseases

Volumn 2, Issue 5, 2008, Pages

  El Tahtawy, Ahmed ^a   Glue, Paul ^a   Andrews, Emma N ^a   Mardekian, Jack ^a   Amsden, Guy W ^a,b   Knirsch, Charles A ^a  

^a PFIZER INC   (United States)

^b BASSETT HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; AZITHROMYCIN; IVERMECTIN; ANTIPARASITIC AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE CONTROL; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; POPULATION MODEL; SIMULATION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; COMPUTER SIMULATION; DRUG INTERACTION; MIDDLE AGED; THEORETICAL MODEL;

ADULT; ANTIPARASITIC AGENTS; AZITHROMYCIN; COMPUTER SIMULATION; DRUG INTERACTIONS; FEMALE; HUMANS; IVERMECTIN; MALE; MIDDLE AGED; MODELS, THEORETICAL; YOUNG ADULT;

EID: 48949118052     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000236     Document Type: Article

References (22)

1. WHO (1998) Global Disease Elimination and Eradication as Public Health Strategies. Bull World Health Org 76 (Suppl 2): 162.
2. Henderson DA (2002) Smallpox. In: Knobler S, Lederberg J, Pray LA, eds. 2002 Considerations for Viral Disease Eradication: Lessons Learned and Future Strategies: Workshop Summary. Washington: National Academy Press. pp 33-63.
3. Technical Consecutive Group (2002) 'Endgame' issues for the global polio eradication initiative. Clin Infect Dis 34: 72-77.
4. Wawer MJ, Sewankambo NK, Serwadda D, Quinn TC, Paxton LA, et al. (1999) Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomized community trial. Lancet 353: 525-535.
5. Amsden G, Gregory T, Michalak C, Glue P, Knirsch C (2007) Pharmacokinetics of azithramycin, and the combination of ivermectin and albendazole, when administered alone and concurrently in healthy volunteers. Am J Trop Med Hyg 76: 1153-1157.
6. Edwards G (2003) Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J 2 Supl 1: S8.
7. Guzzo CA, Furtek CI, Porras AG, Chen C, Tipping R, et al. (2002) Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 42: 1122-1133.
8. Ivermectin product label (http://www.fda.gov/cder/foi/label/2003/ 50742slr011§romectol〈l.pdf).
9. Holford NH (1996) A size standard for pharmacokinetics. Clin Pharmacokinet 30: 329-332.
10. Beal SL, Sheiner LB (1988) NONMEM Users Guide - Part I-VIII. University of California at San Francisco, San Francisco, NONMEM Project Group C255, University of California at San Francisco, San Francisco.
11. Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/ pharmaco-dynamic models using the posterior predictive check. J. Pharmacokinet Biopharm 28: 171-192.
12. Na-Bangchang Y, Kietinun S, Pawa KK, Hanpitakpong W, Na-Bangchang C, Lazdins J (2006) Assessments of pharmacokinetic drug interactions and tolerability of albendazole, praziquantel and ivermectin combinations. Trans Royal Soc Trop Med Hygiene 100: 335-345.
13. Awadzi Y, Edwards G, Duke BOL, Opuku NO, Attah SK, et al. (2003) The co-administration of ivermectin and albendazole - safety, pharmacokinetics and efficacy against Onchocerca volvulus. Ann Trop Med Pathol 97: 165-178.
14. Awadzi K, Edwards G, Opoku NO, Ardrey AE, Favager S, et al. (2004) The safety, tolerability and pharmacokinetics of levamisole alone, levamisole plus ivermectin, and levamisole plus albendazole, and their efficacy against Onchocerca volvulus. Ann Trop Med Pathol 98: 595-614.
15. Cerkvenik Flajs V, Grabnar I (2002) Ivermectin pharmacokinetics. Slov Vet Res 39: 167-178.
16. Zeng Z, Andrew NW, Arison BH, Luffer-Atlas D, Wang RW (1998) Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human river microsomes. Xenobiotica 28: 313-321.
17. Molento MM, Lifschitz A, Sallovitz J, Lamisse C, Pritchard R (2004) Influence of verapamil on the pharmacokinetics of the antiparasitic drugs ivermectin and moxidectin in sheep. Parasitol Res 92: 121-127.
18. Schinkel AH, Smit JJM, van Telligen O, Beijnen JH, Wagenaar E, et al. (1994) Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502.
19. Lespine A, Dupuy J, Orlowski S, Nagy T, Glavinas H, Krajcsi P, Alvinerie M (2006) Interaction of ivermectin with multidrug resistance proteins (MRPI, 2 and 3). Chemico-Biol Interactions 159: 169-179.
20. Schrickx JA, Fink-Gremmels J (2006) Ex vivo P-glycoprotein inhibition in porcine lymphocytes. J Vet Pharmacol Ther 29 (s1): 120.
21. Frame B, Miller R, Lalonde RL (2003) Evaluation of mixture modeling with count data using NONMEM. J Pharmacokinet Pharmacodynam 30: 167-183.
22. Ito K, Ogihara Y, Kanamitsu S, Itoh T (2003) Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Disp 31: 945-954.